[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[Purpose] In order to verify the performance and functionality of RTP as the early nutrition indicator, we conducted the multi-facilities joint trial by NST operated facilities in Japan.
[Subject and Methodology] We monitored and investigated the time-dependent transition of ALB and RTP for acute-phase disease and chronic phase disease. Additionally, we created 2×2 contingency table with the group which ingested energy volume satisfies the basal metabolic energy consumption, the group which ingested energy volume does not satisfy the basal metabolic energy consumption, the group which shows 100% or higher of the relative variability on 14th day and the group which shows 99% or less of the relative variability on 14th day when considering the value of ALB and RTP on 7th day after NST intervention as 100%. Then, we performed the comparative analysis of sensitivity, specificity, and effectiveness.
[Result] For acute-phase disease, while ALB was elevated again on 14th day after the surgery, RTP was recognized its elevation on 7th day after the surgery. For chronic phase disease, even after NST intervention, ALB and RTP underwent a transition slowly and any major change was not found on 7th. However, RTP was recognized its elevation on 14th again. The sensitivity of acute-phase disease was ALB<RBP<Tf = TTR and the specificity was ALB<Tf<RBP<TTR. The sensitivity of chronic phase disease was ALB<Tf=RBP=TTR and the specificity was all 50% and there was no difference. The effectiveness of acutephase disease was ALB<Tf<RBP<TTR and the effectiveness of chronic phase disease showed that RTP was superior to ALB.
[Conclusion] RTP assay for targeting acute-phase disease and chronic phase disease was suggested to reflect perceptively the nutrition condition comparing with the variation of ALB. The development high quality nutrition therapy is expected by using RTP for monitoring mainly by NST on the determination of the effective of the nutrition therapy for various diseases in the future.

View full abstract

Aim: Insulin resistance and impaired ammonia metabolism are involved in the disease progression of chronic liver diseases. ANOM^® is a concentrated liquid diet which contains various types of nutrients modulating glucose and ammonia metabolisms. The aim of this study is to investigate effects of ANOM^® on insulin resistance and ammonia metabolism in patients with chronic liver disease.
Patients and Methods: Eight patients with hepatitis C virus (HCV)-related chronic liver disease were enrolled in this study, and were given ANOM^® (1pack/day) as a late evening snack for 3 months. After administration of ANOM^®, energy intake was calculated by 3-day diet recording method, and body composition was measured by a multi-frequency bioelectric impedance analyzer. Furthermore, biochemical examinations was performed, and quality of life was evaluated with Medical Outcomes Study 36-Item Short-Form Health Survey version 2 (SF-36v2). These parameters were compared to those before administration of ANOM^®.
Results: There was no significant change in energy intake and any body composition between before and after administration of ANOM^®. No significant change was also seen in plasma glucose level, plasma hemoglobinA1c value, serum insulin level, HOMA-IR value, and SF-36v2 scores between before and after administration of ANOM^®. However, blood ammonia level was significantly decreased after administration of ANOM^® compare to that before administration (53.9 ± 30.2 vs. 41.5 ± 23.3 μg/dL, p=0.018).
Conclusion: ANOM^® significantly improved ammonia metabolism, but not insulin resistance, in patients with HCV-related chronic liver disease.

View full abstract